Table 2.
Selected list of approved antibodies produced in CHO cells
| Product | Indication | Marketing company | First US approval |
| Rituximab (Rituxan™) | Chronic lymphocytic leukemia | Genentech (Roche), Biogen Idec | 1997 |
| Trastuzumab (Herceptin™) | Breast cancer | Genentech (Roche) | 1998 |
| Alemtuzumab (Campath™) | Chronic lymphocytic leukemia | Genzyme | 2001 |
| Omalizumab (Xolair™) | Allergic asthma | Genentech (Roche) | 2003 |
| Bevacizumab (Avastin™) | Colorectal cancer | Genentech (Roche) | 2004 |
| Panitumumab (Vectibix™) | Colorectal cancer | Amgen | 2006 |
| Tocilizumab (Actemra™) | Rheumatoid arthritis | Chugai/Roche | 2010 |